Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunotherapy in lung cancer.

Literature DB >> 9703271

Immunotherapy in lung cancer.

M Al-Moundhri, M O'Brien, B E Souberbielle.

Abstract

More research and new treatment options are needed in all stages of lung cancer. To this end immunotherapy needs a revival in view of recent improved technologies and greater understanding of the underlying biology. In this review we discuss mechanisms of tumour immunotherapy, non-specific, specific and adoptive, with particular reference to a direct therapeutic action on all subtypes of lung cancer.

Entities: Disease

Mesh：

Substances：

Year: 1998 PMID： 9703271 PMCID： PMC2063029 DOI： 10.1038/bjc.1998.486

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

68 in total

1. Natural interferon alfa as maintenance therapy for small cell lung cancer.

Authors: K Mattson; A Niiranen; S Pyrhönen; L R Holsti; P Holsti; E Kumpulainen; K Cantell
Journal: Eur J Cancer Date: 1992 Impact factor: 9.162

2. Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens.

Authors: A Hollinshead; T H Stewart; H Takita; M Dalbow; J Concannon
Journal: Cancer Date: 1987-09-15 Impact factor: 6.860

3. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors: S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal: Ann Surg Date: 1989-10 Impact factor: 12.969

4. Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): a phase II study.

Authors: A Bowman; R J Fergusson; S G Allan; M E Stewart; A Gregor; M A Cornbleet; A P Greening; G K Crompton; R C Leonard; J F Smyth
Journal: Ann Oncol Date: 1990-09 Impact factor: 32.976

5. Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha.

Authors: S C Yang; L Owen-Schaub; A Mendiguren-Rodriguez; E A Grimm; W K Hong; J A Roth
Journal: J Thorac Cardiovasc Surg Date: 1990-01 Impact factor: 5.209

6. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer.

Authors: R L Kradin; J T Kurnick; D S Lazarus; F I Preffer; S M Dubinett; C E Pinto; J Gifford; E Davidson; B Grove; R J Callahan
Journal: Lancet Date: 1989-03-18 Impact factor: 79.321

7. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects.

Authors: A Faradji; A Bohbot; M Schmitt-Goguel; N Roeslin; S Dumont; M L Wiesel; C Lallot; M Eber; J Bartholeyns; P Poindron
Journal: Cancer Immunol Immunother Date: 1991 Impact factor: 6.968

8. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer.

Authors: R L Jansen; R Slingerland; S H Goey; C R Franks; R L Bolhuis; G Stoter
Journal: J Immunother (1991) Date: 1992-07

9. Adjuvant, specific, active immunotherapy for resectable squamous cell lung carcinoma: a 5-year survival analysis.

Authors: H Takita; A C Hollinshead; R H Adler; J Bhayana; M Ramundo; R Moskowitz; U N Rao; S Raman
Journal: J Surg Oncol Date: 1991-01 Impact factor: 3.454

10. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor.

Authors: I Yoshino; T Yano; M Murata; T Ishida; K Sugimachi; G Kimura; K Nomoto
Journal: Cancer Res Date: 1992-02-15 Impact factor: 12.701

6 in total

Review 1. Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention.

Authors: Martin R Jadus; Josephine Natividad; Anthony Mai; Yi Ouyang; Nils Lambrecht; Sandor Szabo; Lisheng Ge; Neil Hoa; Maria G Dacosta-Iyer
Journal: Clin Dev Immunol Date: 2012-07-29

2. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.

Authors: M E O'Brien; A Saini; I E Smith; A Webb; K Gregory; R Mendes; C Ryan; K Priest; K V Bromelow; R D Palmer; N Tuckwell; D A Kennard; B E Souberbielle
Journal: Br J Cancer Date: 2000-10 Impact factor: 7.640

Review 3. Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types.

Authors: Tara C Gangadhar; April Ks Salama
Journal: Onco Targets Ther Date: 2015-04-22 Impact factor: 4.147